[
  {
    "ts": null,
    "headline": "JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won",
    "summary": "Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.",
    "url": "https://finnhub.io/api/news?id=7d06c927eaadf8f0888bcb67eceeb5786d758e8a3ef1c73fd175c9246e4664ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768243022,
      "headline": "JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won",
      "id": 138078023,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.",
      "url": "https://finnhub.io/api/news?id=7d06c927eaadf8f0888bcb67eceeb5786d758e8a3ef1c73fd175c9246e4664ec"
    }
  },
  {
    "ts": null,
    "headline": "Tempus Shares Jump After Strong Preliminary 2025 Results",
    "summary": "Investors Eye 2026 Guidance as Tempus AI Tops $1.1B in Contract Value",
    "url": "https://finnhub.io/api/news?id=686979a1fb16905d5efaf87fbfd2069526ea76d5517eb4566138dbd0b9d79802",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768242932,
      "headline": "Tempus Shares Jump After Strong Preliminary 2025 Results",
      "id": 138078087,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors Eye 2026 Guidance as Tempus AI Tops $1.1B in Contract Value",
      "url": "https://finnhub.io/api/news?id=686979a1fb16905d5efaf87fbfd2069526ea76d5517eb4566138dbd0b9d79802"
    }
  },
  {
    "ts": null,
    "headline": "Tempus AI's Pharma Momentum Accelerates",
    "summary": "Contract value passes $1.1 billion milestone",
    "url": "https://finnhub.io/api/news?id=ff38bcbc57cd472afc636a8380f0ee88a6ef9e41608fd3600c0ae3a53b8bd375",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768241298,
      "headline": "Tempus AI's Pharma Momentum Accelerates",
      "id": 138078032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Contract value passes $1.1 billion milestone",
      "url": "https://finnhub.io/api/news?id=ff38bcbc57cd472afc636a8380f0ee88a6ef9e41608fd3600c0ae3a53b8bd375"
    }
  },
  {
    "ts": null,
    "headline": "‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News.",
    "summary": "Monday is the first day of  J.P. Morgan’s  annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year.  There is ample precedent: Last year,  Johnson & Johnson  announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering.  The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.",
    "url": "https://finnhub.io/api/news?id=a8e42fa0176125b6d61a239d1fc7e9d3ac654534ef8fe6ce6ee1a22fdfcc0ed8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768235880,
      "headline": "‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News.",
      "id": 138076408,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Monday is the first day of  J.P. Morgan’s  annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year.  There is ample precedent: Last year,  Johnson & Johnson  announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering.  The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.",
      "url": "https://finnhub.io/api/news?id=a8e42fa0176125b6d61a239d1fc7e9d3ac654534ef8fe6ce6ee1a22fdfcc0ed8"
    }
  },
  {
    "ts": null,
    "headline": "MDGL Secures Exclusive Global Right for MASH Treatment From PFE",
    "summary": "Madrigal Pharmaceuticals obtains global rights to Pfizer's ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for MASH.",
    "url": "https://finnhub.io/api/news?id=25d9e4d8362a98ea714fe2a9a92ea5bced671e5f9160d3b9769929791e08ccc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768234800,
      "headline": "MDGL Secures Exclusive Global Right for MASH Treatment From PFE",
      "id": 138076571,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Madrigal Pharmaceuticals obtains global rights to Pfizer's ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for MASH.",
      "url": "https://finnhub.io/api/news?id=25d9e4d8362a98ea714fe2a9a92ea5bced671e5f9160d3b9769929791e08ccc9"
    }
  },
  {
    "ts": null,
    "headline": "JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop",
    "summary": "Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.",
    "url": "https://finnhub.io/api/news?id=2456321ad8aeb8e87be5ce09b3b73a9921624b75046cb6673018393867e14bb6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768233395,
      "headline": "JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop",
      "id": 138075160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.",
      "url": "https://finnhub.io/api/news?id=2456321ad8aeb8e87be5ce09b3b73a9921624b75046cb6673018393867e14bb6"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript",
    "summary": "Pfizer Inc. (PFE) 44th Annual J.P.",
    "url": "https://finnhub.io/api/news?id=45e2853ce848fe661e3360ba9d8273d456d5a07cb20328370dcc872a755d5189",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768230960,
      "headline": "Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript",
      "id": 138078223,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. (PFE) 44th Annual J.P.",
      "url": "https://finnhub.io/api/news?id=45e2853ce848fe661e3360ba9d8273d456d5a07cb20328370dcc872a755d5189"
    }
  },
  {
    "ts": null,
    "headline": "CD22 Targeted Therapies Market Research Report 2025-2026: Opportunities Lie in Developing Precise CD22 Targeted Therapies for Blood Cancers, with Over 20 Ongoing Clinical Trials",
    "summary": "The main market opportunities lie in developing precise CD22 targeted therapies for blood cancers, with over 20 ongoing clinical trials. Innovative technologies like TALEN® are enhancing cell-based therapies. Key players like Pfizer and emerging biotechs are driving advancements, creating growth prospects in this evolving sector.Dublin, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The \"CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026\" report has been",
    "url": "https://finnhub.io/api/news?id=c3df3d4a6fb34fb02fda81f1fa48779b44ecb9371cd17cc88b9c255cf837628f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768228860,
      "headline": "CD22 Targeted Therapies Market Research Report 2025-2026: Opportunities Lie in Developing Precise CD22 Targeted Therapies for Blood Cancers, with Over 20 Ongoing Clinical Trials",
      "id": 138072402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The main market opportunities lie in developing precise CD22 targeted therapies for blood cancers, with over 20 ongoing clinical trials. Innovative technologies like TALEN® are enhancing cell-based therapies. Key players like Pfizer and emerging biotechs are driving advancements, creating growth prospects in this evolving sector.Dublin, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The \"CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026\" report has been",
      "url": "https://finnhub.io/api/news?id=c3df3d4a6fb34fb02fda81f1fa48779b44ecb9371cd17cc88b9c255cf837628f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations",
    "summary": "AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",
    "url": "https://finnhub.io/api/news?id=4c5cd43b9789dda93c2e7019c0a76364351620a7132db313a44e9fefec4c074b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768217040,
      "headline": "AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations",
      "id": 138075441,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",
      "url": "https://finnhub.io/api/news?id=4c5cd43b9789dda93c2e7019c0a76364351620a7132db313a44e9fefec4c074b"
    }
  }
]